Jim Cramer Discusses Sentiment Surrounding Pfizer (PFE)

We recently published 14 Stocks Jim Cramer Discussed Including His 2 Top Quantum Computing Stocks. Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed.

Pfizer Inc. (NYSE:PFE)’s shares are down by 10% year-to-date. In this appearance, Cramer discussed the firm’s $43 billion acquisition of drug company Seagen. Cramer has commented on the acquisition several times in 2025. For instance, in January, he stated that Pfizer Inc. (NYSE:PFE) had yet to launch any breakout drugs that would justify the deal. However, in March, Cramer was optimistic about the acquisition as he expected the deal to be “great.” This time, he commented on the overall sentiment surrounding Pfizer Inc. (NYSE:PFE):

“Pfizer is being viewed as a company that doesn’t really have anything. Meaning that people feel that the Seagen acquisition didn’t pay off. That was a very big acquisition. I don’t wanna write them off, but it’s kind of like cholesterol. . .where you finally just, you know you got a number of players in it, and everybody did well. I think that can happen here.”

Pfizer Inc. (NYSE:PFE) announced in September that it would showcase its cancer drug portfolio at an oncology conference due to be held in Berlin, Germany, next month. This portfolio includes phase three results of its bladder and prostate cancer drugs and phase two results of its small cell lung cancer treatment.

While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.